The clinical efficacy of combined ESA and Roxadustat treatment for renal anemia in hemodialysis patients with secondary hyperparathyroidism

Abstract

Abstract Objective: To investigate the efficacy and safety of combined Roxadustat and erythropoiesis stimulator (ESA) treatment of renal anemia in hemodialysis patients with secondary hyperparathyroidism. Methods: A retrospective analysis was conducted on hemodialysis patients with renal anemia and secondary hyperparathyroidism treated with ESAs alone, who were admitted to our hospital from March 2022 to December 2022. The patients were treated with Roxadustat combined with ESAs for 3 months, and the changes in Hb levels and laboratory related indicators before and after the combined treatment were analyzed. Results: The results showed that a total of 21 patients received combination therapy, with a significant increase in Hb compared to ESAs alone (t=-5.32, P<0.001). The Hb qualification rate was 33.33%, and the ∆Hb response rate was 71.43%; The parathyroid hormone significantly decreased, with a statistically significant difference (Z=-2.033b, P<0.05); Hemoglobin (RBC) and Total iron binding capacity (TIBC) were significantly increased compared to ESAs alone; Total cholesterol (TC) and Low-density lipoprotein (L-DLC) were significantly lower than ESAs alone, and High-density lipoprotein (H-DLC) was slightly lower than ESAs alone; The differences in the changes in the above indicators were statistically significant (P<0.05). There was no statistically significant difference in changes in other laboratory related indicators (P>0.05). No adverse reactions were observed during the combined treatment of 21 patients. Conclusion: The combination of Roxadustat and ESAs can effectively improve renal anemia in hemodialysis patients with secondary hyperparathyroidism, as well as improve indicators of hyperparathyroidism and blood lipid levels with high levels of safety. This combined treatment thus provides a new and safe treatment method for these patients.